Millar, J.; Millward, Michael - In: PharmacoEconomics 25 (2007) 5, pp. 429-442
The results suggest that trastuzumab as adjuvant therapy for early breast cancer may be cost effective when given over either 52 or 9 weeks at current acquisition costs in Australia. However, the overall budget impact of the 52-week course is significant, and the 9-week course appears...